158 related articles for article (PubMed ID: 25338223)
1. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer.
Lindsey SC; Ganly I; Palmer F; Tuttle RM
Thyroid; 2015 Feb; 25(2):242-9. PubMed ID: 25338223
[TBL] [Abstract][Full Text] [Related]
2. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
Kwon H; Kim WG; Jeon MJ; Song DE; Lee YM; Sung TY; Chung KW; Yoon JH; Hong SJ; Baek JH; Lee JH; Kim TY; Kim WB; Shong YK
Endocrine; 2016 Jul; 53(1):174-81. PubMed ID: 26754662
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.
Vaisman F; Momesso D; Bulzico DA; Pessoa CH; Dias F; Corbo R; Vaisman M; Tuttle RM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):132-8. PubMed ID: 22248037
[TBL] [Abstract][Full Text] [Related]
4. Dynamic risk stratification in medullary thyroid carcinoma: Single institution experiences.
Choi JB; Lee SG; Kim MJ; Kim TH; Ban EJ; Lee CR; Lee J; Kang SW; Jeong JJ; Nam KH; Chung WY
Medicine (Baltimore); 2018 Jan; 97(3):e9686. PubMed ID: 29505021
[TBL] [Abstract][Full Text] [Related]
5. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.
Pitoia F; Jerkovich F; Urciuoli C; Schmidt A; Abelleira E; Bueno F; Cross G; Tuttle RM
Thyroid; 2015 Nov; 25(11):1235-42. PubMed ID: 26132983
[TBL] [Abstract][Full Text] [Related]
6. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging.
Tuttle RM; Ganly I
Oral Oncol; 2013 Jul; 49(7):695-701. PubMed ID: 23601563
[TBL] [Abstract][Full Text] [Related]
9. Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer.
Yang JH; Lindsey SC; Camacho CP; Valente FO; Germano-Neto F; Machado AL; Mamone MC; Brodskyn F; Biscolla RP; Tuttle RM; Dias-da-Silva MR; Maciel RM
Clin Endocrinol (Oxf); 2015 Dec; 83(6):938-42. PubMed ID: 25376110
[TBL] [Abstract][Full Text] [Related]
10. Determinants of life expectancy in medullary thyroid cancer: age does not matter.
de Groot JW; Plukker JT; Wolffenbuttel BH; Wiggers T; Sluiter WJ; Links TP
Clin Endocrinol (Oxf); 2006 Dec; 65(6):729-36. PubMed ID: 17121523
[TBL] [Abstract][Full Text] [Related]
11. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
12. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
13. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
14. Fewer cancer reoperations for medullary thyroid cancer after initial surgery according to ATA guidelines.
Verbeek HH; Meijer JA; Zandee WT; Kramp KH; Sluiter WJ; Smit JW; Kievit J; Links TP; Plukker JT
Ann Surg Oncol; 2015 Apr; 22(4):1207-13. PubMed ID: 25316487
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
[TBL] [Abstract][Full Text] [Related]
16. Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer.
Adam MA; Thomas S; Roman SA; Hyslop T; Sosa JA
JAMA Surg; 2017 Sep; 152(9):869-876. PubMed ID: 28636692
[TBL] [Abstract][Full Text] [Related]
17. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system.
Machens A; Dralle H
Ann Surg; 2013 Feb; 257(2):323-9. PubMed ID: 22968075
[TBL] [Abstract][Full Text] [Related]
19. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer.
Vaisman F; Shaha A; Fish S; Michael Tuttle R
Clin Endocrinol (Oxf); 2011 Jul; 75(1):112-9. PubMed ID: 21521273
[TBL] [Abstract][Full Text] [Related]
20. Long-term prognosis of medullary thyroid carcinoma.
Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
